Goldman Sachs raises its target price to $28 on Neutral-rated Carefusion CFN on incrementally higher confidence in the company's long term outlook.
Goldman Sachs says, "Longer-term, the company remains focused on building a
foundation for growth – improving/streamlining infrastructure (should reduce SG&A) and bolstering the pipeline (through both internal R&D and M&A). We see strategic activity as a key driver for the stock."
CFN closed at $25.24 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in